Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): A 26-week oral tablet administration of ENADA®/NADH for chronic toxicity study in rats

Drugs under Experimental and Clinical Research

Volumn 28, Issue 5, 2002, Pages 185-192

  Birkmayer, J G D ^a,b,c   Nadlinger, K ^a  

^a Birkmayer Laboratories ^*  (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c Birkmayer Pharmaceuticals   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BICARBONATE; ENADA; EUDRAGIT; MAGNESIUM STEARATE; MANNITOL; MICROCRYSTALLINE CELLULOSE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL CHEMISTRY; CLINICAL FEATURE; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; FEMALE; FOOD INTAKE; HEMATOLOGY; HISTOLOGY; MALE; MORTALITY; NONHUMAN; ORGAN WEIGHT; RAT; TABLET; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; DRUG STABILITY; EATING; FEMALE; MALE; NAD; ORGAN SIZE; RATS; RATS, INBRED STRAINS; TABLETS; TOXICITY TESTS, CHRONIC;

EID: 0037005004     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Birkmayer J.G.D. Stable, ingestable and absorbable NAD and NADPH therapeutic compositions. United States Patent Number 5,332,727, 1994.
2. Birkmayer J.G.D. Stable, ingestable and absorbable NAD and NADPH therapeutic compositions. European Patent, Patent Number EP 0 697 859 B1, 1994.
3. Forsyth L.M., Preuss H.G., MacDowell A.L., Chiazze L., Birkmayer G.D., Bellanti J.A. Therapeutic effects of oral NAD on the symptoms of patients with chronic fatigue syndrome. Annals Allergy, Asthma Immunol., 82, 185, 1999.
4. Levene H. "Robust test for equality of variance in contributions to probability and statistics." In: Olkin I. (Ed.). Contributions to Probability and Statistics. Stanford University Press, Palo Alto, 1960, pp. 278-92.
5. Lehmann E.L. "Nonparametrics: Statistical Methods Based on Ranks." McGraw-Hill, New York, 1975.
6. Armitage P. "Statistical Methods in Medical Research." Blackwell, Oxford, 1971.
7. Snedecor G.W., Cochran W.G. "Statistical Methods." 7th Edition, Iowa State University Press, Iowa, 1980.
8. Mattern C. "Zur Entwicklung von stabilen Arzneiformen des Coenzyms NAD für die perorale und parenterale Applikation." Doctoral Thesis, Humboldt University, Berlin, 1996.
9. Busheri N., Jarell S.T., Liebermann S., Mirdamadi-Zonozi N., Birkmayer G., Preuss H.G. Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Geriatric Nephrol Urol., 8, 100, 1998.
10. Rex A., Hentschke M.-P., Fink H. Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) ih the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy. Pharmacol. Toxicol., 90, 220, 2002.
11. Birkmayer G., Nadlinger K. On the safety of reduced nicotinamide adenine dinucleotide (NADH). J. Env. Path Tox. Onc.